Xilio Therapeutics (XLO) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Xilio Therapeutics (XLO) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 23.5% versus a loss of 62.7%. Xilio Therapeutics is the larger company by market cap ($59.3 million vs $54.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | XLO | ZYBT |
|---|---|---|
| Share price | $9.01 | $1.15 |
| Market cap | $59.29M | $54.50M |
| 1-day change | 0.00% | -0.87% |
| YTD return | +0.56% | -0.01% |
| 1-year return | -23.48% | -62.67% |
| EPS (TTM) | $-0.60 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.59 | $8.01 |
| 52-week low | $6.47 | $0.616 |
| Distance from 52-week high | -28.41% | -85.64% |
| Analyst consensus | none | — |
| Avg. price target upside | +121.98% | — |
| Average volume | 19.07K | 5.10M |
| Shares outstanding | 6.58M | 47.39M |
| Employees | 76 | 269 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XLO has outperformed ZYBT by 39.2 percentage points over the past year.
About Xilio Therapeutics
XLO stock →Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Healthcare · Biotechnology · 76 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Healthcare · Drug Manufacturers - Specialty & Generic · 269 employees
XLO vs ZYBT FAQ
Which is bigger, Xilio Therapeutics or Zhengye Biotechnology?
Xilio Therapeutics (XLO) is larger, with a market capitalization of $59.29M compared with $54.50M for Zhengye Biotechnology (ZYBT).
Which stock has performed better over the past year, XLO or ZYBT?
XLO returned -23.48% over the past 12 months, compared with -62.67% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are Xilio Therapeutics and Zhengye Biotechnology in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Xilio Therapeutics and Drug Manufacturers - Specialty & Generic for Zhengye Biotechnology.